Table 3.
Incidence of abnormal autonomic measurements at EDIC year 13/14 among subjects with intact function at DCCT closeout
| Characteristic | Group | Incident Abnormal Function, No. (%) |
Unadjusted Odds Ratio (95% CI) |
Adjusted Odds Ratio (95% CI)c |
HbA1c Adjusted Odds Ratio (95% CI)c |
|---|---|---|---|---|---|
| R-R Variation < 15 | INT | 109 (18.8) | 0.76 (0.57–1.02) | 0.70 (0.51–0.96) | 1.36 (0.84–2.19) |
| CONV | 125 (23.2) | ||||
| Valsalva Ratio ≤ 1.5 | INT | 113 (19.7) | 0.92 (0.69–1.23) | 0.85 (0.62–1.16) | 0.86 (0.54–1.36) |
| CONV | 112 (21.1) | ||||
| Abnormal CAN function b | INT | 141 (24.4)a | 0.76 (0.59–0.995) | 0.69 (0.51–0.93) | 1.31 (0.83–2.07) |
| CONV | 159 (29.8) |
CAN Cardiac autonomic neuropathy, EDIC Epidemiology of Diabetes Interventions and Complications, DCCT Diabetes Control and Complications Trial, INT intensive, CONV conventional
P < 0.05 for treatment group differences by the chi-square test comparing INT and CONV treatment groups.
Abnormal CAN function was defined as any one of the following conditions: R-R variation < 15; R-R variation < 20 in combination with Valsalva ratio ≤ 1.5; or Postural hypotension.
Logistic regression models were adjusted for DCCT baseline age, sex, cohort assignment and duration in the DCCT study. Models for R-R variation <15 were also adjusted for R-R variation at DCCT closeout, models for Valsalva ratio ≤ 1.5 adjusted for Valsalva ratio at DCCT closeout, and models for abnormal CAN function adjusted for both quantitative measures. HbA1c models include both the mean HbA1c level during DCCT and during EDIC.